JAK Inhibitor Selectivity in Detail
On this page
Direct answer
Four Janus kinases transcribe more than fifty cytokine signals, and every JAK inhibitor is a bet on which one to silence. JAK2 carries erythropoietin and thrombopoietin, so JAK2 blockade costs anaemia and cytopenias; JAK3 sits on the common gamma chain of lymphocyte cytokines (IL-2, 4, 7, 9, 15, 21); JAK1 channels most inflammatory signals; TYK2 handles IL-12, IL-23 and type I interferons. Tofacitinib (JAK1/3) treats rheumatoid arthritis, psoriasis and ulcerative colitis; baricitinib (JAK1/2) and upadacitinib (JAK1) treat RA and atopic dermatitis; ruxolitinib (JAK1/2) treats myelofibrosis — where blocking JAK2 is the point, not the price. The 2021 ORAL Surveillance trial drove class-wide boxed warnings: serious infection, malignancy, venous thromboembolism and major cardiac events versus TNF inhibitors in vulnerable patients.
What you must remember
- Selectivity map: tofacitinib JAK1/3, 5 mg twice daily; baricitinib JAK1/2, 4 mg daily; upadacitinib JAK1-selective, 15 mg; abrocitinib JAK1, for atopic dermatitis; ruxolitinib JAK1/2 (myelofibrosis, polycythaemia vera, topical for vitiligo); fedratinib JAK2 (myelofibrosis).
- Toxicity logic: JAK2 inhibition → anaemia, neutropenia, thrombocytopenia; JAK1/JAK3 broadly → infection and malignancy surveillance; the profile follows the cytokines, not the brand.
- Class boxed warnings (post-ORAL Surveillance): serious infections, malignancy, venous thromboembolism, major adverse cardiac events — tofacitinib versus TNF inhibitors in patients aged 50 and above with cardiovascular risk rewrote the class label.
- Deucravacitinib: allosteric TYK2 inhibitor binding the pseudokinase (JH2) domain rather than the active site — cleaner selectivity, approved for psoriasis; the exam's favourite recent addition.
- Topical ruxolitinib: the first FDA-approved therapy to repigment vitiligo (2022) — a dermatology crossover worth quoting.
- Screening before starting: latent TB, hepatitis B and C, zoster history (shingles risk is high); full blood count and lipids at baseline and follow-up; avoid live vaccines.
- Dose adjustments: reductions in moderate renal impairment and hepatic impairment; cytopenia thresholds gate initiation.
- Repurposing footnote: baricitinib won COVID-19 approval (ACTT-2) — JAK inhibition as anticytokine therapy, with AAK1 effects speculated.
Reading the selectivity like a haematologist
The map becomes intuitive when each JAK is attached to its owners. Myelofibrosis patients suffer from constitutively active JAK2 signalling — spleen enlargement, night sweats, cachexia — so ruxolitinib, a JAK1/2 inhibitor, treats the disease's engine even though it drops haemoglobin and platelets; the monitoring is blood counts, because the target is haematopoietic. Rheumatoid arthritis wants JAK1's inflammatory cytokines and JAK3's lymphocyte signalling, but wants EPO and TPO left alone — hence upadacitinib's JAK1 selectivity buys anaemia-avoidance, and why haemoglobin checks matter more on baricitinib than on tofacitinib. Deucravacitinib pushes the logic to its end: by binding TYK2's pseudokinase domain allosterically, it spares the catalytic site shared across the family, cutting cross-reactive toxicity — the pharmacological argument for why "selectivity" now means binding-site choice as much as target choice. Add ORAL Surveillance and the caution: selectivity mitigates haematologic cost, not the class-wide infection, VTE and malignancy signal in older, risk-laden patients. The student who walks this chain — cytokine, JAK, drug, monitorable toxicity — answers any JAK question thrown at them.
Where students slip
The first slip is equating selectivity with safety wholesale — JAK1-selective drugs avoid anaemia but inherit the boxed warnings; ORAL Surveillance used tofacitinib, and the class label followed. The second is misassigning targets: baricitinib is JAK1/2 (not JAK3), tofacitinib is JAK1/3 — the pairs matter because JAK2 ownership of haematopoiesis is the toxicity axis. Third, students forget ruxolitinib's dermatology crossover — topical vitiligo repigmentation — which is now a favourite one-liner. Fourth, the screening set is treated as oncology-flavoured ritual: TB, hepatitis, zoster and baseline counts are as mandatory here as for any biologic, with shingles the signature risk. Fifth, deucravacitinib gets filed as "another JAK inhibitor" without its allosteric distinction — the one structural innovation in the class that changed the toxicity conversation. Finally, thrombosis: the VTE signal concentrates in older patients with risk factors, so the practical rule is age-plus-comorbidity gating, not blanket fear — and saying exactly that is the mark.
Frequently asked questions
Which JAK does tofacitinib inhibit?
JAK1 and JAK3 — matching its inflammatory and lymphocyte-cytokine indications while sparing JAK2-driven haematopoiesis partially.
Why does JAK2 inhibition cause anaemia?
Erythropoietin and thrombopoietin signal through JAK2, so blockade suppresses red cell and platelet production.
What did the ORAL Surveillance trial change?
Tofacitinib showed higher rates of serious infection, malignancy, VTE and major cardiac events than TNF inhibitors in older at-risk patients, driving class-wide boxed warnings.
How is deucravacitinib different from other JAK inhibitors?
It binds TYK2's pseudokinase domain allosterically rather than the conserved catalytic site, achieving cleaner selectivity.
Which JAK inhibitor repigments vitiligo?
Topical ruxolitinib — the first FDA-approved treatment to restore pigment in nonsegmental vitiligo.